Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Pharmaceuticals (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on targeted therapies for breast cancer, has granted stock options to three new employees. The grants, approved by the Compensation Committee and issued under the company's 2022 Inducement Plan, allow the purchase of 26,200 shares of common stock at $5.57 per share.
The options, effective January 2, 2025, have a 10-year term and vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in 36 equal monthly installments over the following three years, contingent on continuous employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement material for new employment.
Olema Pharmaceuticals (Nasdaq: OLMA), un'azienda biofarmaceutica in fase clinica focalizzata su terapie mirate per il cancro al seno, ha concesso opzioni su azioni a tre nuovi dipendenti. Le concessioni, approvate dal Comitato di Compensazione e emesse sotto il Piano di Induzione 2022 dell'azienda, consentono l'acquisto di 26.200 azioni ordinarie a 5,57 dollari per azione.
Le opzioni, valide a partire dal 2 gennaio 2025, hanno una durata di 10 anni e maturano in quattro anni, con il 25% che matura al primo anniversario e il restante 75% che matura in 36 rate mensili uguali nel corso dei tre anni successivi, subordinato a un impiego continuativo. Queste concessioni sono state effettuate in conformità alla Regola di Quotazione Nasdaq 5635(c)(4) come incentivo per nuove assunzioni.
Olema Pharmaceuticals (Nasdaq: OLMA), una empresa biofarmacéutica en etapa clínica centrada en terapias dirigidas para el cáncer de mama, ha otorgado opciones sobre acciones a tres nuevos empleados. Las concesiones, aprobadas por el Comité de Compensación y emitidas bajo el Plan de Inducción 2022 de la empresa, permiten la compra de 26,200 acciones ordinarias a $5.57 por acción.
Las opciones, efectivas a partir del 2 de enero de 2025, tienen un plazo de 10 años y se consolidan a lo largo de cuatro años, con un 25% consolidándose en el primer aniversario y el 75% restante consolidándose en 36 cuotas mensuales iguales durante los tres años siguientes, condicionado a empleo continuo. Estas concesiones se realizaron de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4) como incentivo para nuevas contrataciones.
올레마 제약 (Nasdaq: OLMA)는 유방암을 위한 표적 치료에 집중하는 임상 단계의 생명공학 회사로, 세 명의 신규 직원에게 스톡 옵션을 부여했습니다. 이 부여는 보상 위원회의 승인을 받아 회사의 2022 유도 계획에 따라 발행되었으며, 26,200주의 보통주를 주당 $5.57에 구매할 수 있도록 허용합니다.
옵션은 2025년 1월 2일부터 효력이 발생하며, 10년 기간을 가지며 4년 동안 분할 지급됩니다. 첫 번째 기념일에 25%가 지급되고, 나머지 75%는 향후 3년 동안 36회의 동일한 월별 할부로 지급되며, 지속적인 고용에 따라 다릅니다. 이러한 부여는 신규 고용에 대한 유인으로서 나스닥 상장규정 5635(c)(4)에 따라 실시되었습니다.
Olema Pharmaceuticals (Nasdaq: OLMA), une entreprise biopharmaceutique en phase clinique axée sur des thérapies ciblées pour le cancer du sein, a accordé des options d'achat d'actions à trois nouveaux employés. Les attributions, approuvées par le Comité de Rémunération et émises dans le cadre du Plan d'Induction 2022 de l'entreprise, permettent l'achat de 26 200 actions ordinaires à 5,57 $ par action.
Les options, prenant effet le 2 janvier 2025, ont une durée de 10 ans et s'acquièrent sur quatre ans, avec 25% acquis lors du premier anniversaire et les 75% restants acquis en 36 versements mensuels égaux au cours des trois années suivantes, sous condition d'un emploi continu. Ces attributions ont été effectuées conformément à la Règle de Cotation Nasdaq 5635(c)(4) en tant que matériel d'incitation pour de nouveaux emplois.
Olema Pharmaceuticals (Nasdaq: OLMA), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf gezielte Therapien gegen Brustkrebs konzentriert, hat drei neuen Mitarbeitern Aktienoptionen gewährt. Die Vergaben, die vom Vergütungsausschuss genehmigt und im Rahmen des Unternehmensplans zur Anwerbung von 2022 ausgegeben wurden, erlauben den Kauf von 26.200 Aktien zu einem Preis von 5,57 $ pro Aktie.
Die Optionen, die am 2. Januar 2025 wirksam werden, haben eine Laufzeit von 10 Jahren und werden über vier Jahre fällig, wobei 25% am ersten Jahrestag und die verbleibenden 75% in 36 gleichmäßigen monatlichen Raten in den folgenden drei Jahren fällig werden, abhängig von einer kontinuierlichen Beschäftigung. Diese Zuschüsse wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für neue Beschäftigungen gewährt.
- None.
- None.
SAN FRANCISCO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to three new employees to purchase an aggregate of 26,200 shares of the Company's common stock, effective as of January 2, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing a potent KAT6 inhibitor (OP-3136). Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit us at www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
How many shares were included in Olema Pharmaceuticals' (OLMA) January 2025 stock option grants?
What is the exercise price for OLMA's January 2025 inducement stock options?
What is the vesting schedule for Olema's (OLMA) January 2025 inducement grants?
How long is the term of OLMA's January 2025 inducement stock options?
